Possibilities for prescribing lansoprazole in the outpatient practice
https://doi.org/10.21518/2079-701X-2019-12-87-92
Abstract
Acid-dependent diseases are an urgent problem of modern gastroenterology. Antisecretory agents are first-line drugs in the treatment of this pathology, the leaders among which are proton pump inhibitors (PPI). Due to the wide representation of this group of drugs in the pharmaceutical market, the doctor is faced with a choice of destination of a PPI and in most cases the choice is determined by aspects of clinical efficacy, safety and profitability. A number of numerous studies have shown the clinical and economic feasibility of using one of the modern representatives of PPI lansoprazole. The use of this drug is presented in a clinical example.
About the Authors
I. G. Pakhomova
Federal State Budgetary Educational Institution of Higher Education «Mechnikov North-Western State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Pakhomova Inna Grigorievna - Cand. of Sci. (Med.), Associate Professor of Ryss Chair of Propaedeutics of Internal Diseases, Gastroenterology and Dietology.
191015, St. Petersburg, Kirochnaya St., 41, Tel.: +7(921) 757-45-60
E. Yu. Pavlova
Federal State Budgetary Educational Institution of Higher Education «Mechnikov North-Western State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Pavlova Elena Yurievna - Cand. of Sci. (Med.), Tiching Assistant of Ryss Chair for Propaedeutics of Internal Diseases, Gastroenterology and Dietology.
191015, St. Petersburg, Kirochnaya St., +7(911) 986-60-44
References
1. Tkachenko E.I., Uspensky Yu.P., Karateev A.E., Pakhomova I.G. Gastroesophageal reflux disease: pathogenetic basis of differentiated therapeutic approach. Experimentalnaya i KUnicheskaya Gastroenterologia. 2009;2:104-114. (In Russ).
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Gastroesophageal reflux disease. Clinical guidelines. M.: Russian Gastroenterological Association, 2014. 23 p.]
3. (In Russ).
4. Tateno M., Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent. Capsule form. Rmsho lyaku 1991;7:51-62.
5. Tolman K.G., Taubel Y., Warrington S. Comparison of the effects of single and repeated doses of lansoprazole and rabeprazole on 24-hours intragastric pH in healthy volunteers. Ros Med. Zhurn. 2007. V. 15;23:1-5. (In Russ).
6. Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М., 2001. 304 с. [Isakov V.A. Proton pump inhibitors: properties and use in gastroenterology. M., 2001. 304 p.] (In Russ).
7. Lazebnik L.B., Bordin D.S., Kozhurina T.S., Masharova A.A., Firsova L.D., Safonova O.V. A patient with heartburn: general practitioner tactics. Lechashchi Vrach. 2009;7:5-8. (In Russ).
8. Hampel H., Abraham N.S., El Serag H.B. et al. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. 2005;143:199-211.
9. Karateev A.E., Uspensky Yu.P., Pakhomova I.G., Nasonov E.L. Use of NSAIDs and esophageal pathology: association with the main symptoms of gastroesophageal reflux disease, incidence of development and risk factors for erosive esophagitis. Experim. i Klin. Gastroenterol. 2008;3:6-11. (In Russ).
10. Sablin O.A., Bakushkin I.A. Clinical and pharmacoeconomic aspects of the treatment of gastroesophageal reflux disease. Consilium Medicum. 2004;3:1-4 (In Russ).
11. Matheson A. J., Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorder. Drugs. 2001;61:1801-1833.
12. Pakhomova I.G. Differentiated approach to pain therapy in chronic pancreatitis. Consillium medicum, Gastroenterologia, 2013;1:5-8. (In Russ).
Review
For citations:
Pakhomova IG, Pavlova EY. Possibilities for prescribing lansoprazole in the outpatient practice. Meditsinskiy sovet = Medical Council. 2019;(12):87-92. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-87-92
Views:
683
Email this article 